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Abstract: Context
While mitotane is the only approved drug for the treatment of adrenocortical carcinoma
(ACC), data on monotherapy in advanced disease is still scarce.
Objective
To assess the efficacy of mitotane in advanced ACC in a contemporary setting and to
identify predictive factors
Design/Setting
Multicenter cohort study of three German referral centers
Patients
127 patients with advanced ACC treated with mitotane monotherapy
Outcome measures
RECIST evaluation. Progression-free and overall survival (PFS, OS) by Kaplan-Meier
method. Predictive factors by Cox-regression.
Results
Twenty-six patients (20.5%) experienced objective response including three with
complete remission. Overall, median PFS was 4.1 months (range 1.0-73) and median
OS 18.5 months (range 1.3-220). Multivariate analysis indicated two main predictive
factors: low tumor burden (<10 tumoral lesions): hazard ratio (HR) for progression of
0.51(p=0.002) and for death of 0.59(p=0.017), and initiation of mitotane at delayed
advanced recurrence: HR 0.35(p<0.001) and 0.34(p<0.001), respectively. Accordingly,
67% of patients with low tumor burden and mitotane initiation ≥360 days after primary
diagnosis experienced a clinical benefit (stable disease >180 days). Patients who
achieved mitotane levels >14 mg/l had significantly better OS (HR 0.42; p=0.003).
Conclusions
With 20.5% the objective response rate was slightly lower than previously reported.
However, more than 20% of patients experienced a long-term disease control >1 year.
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In general, patients with late diagnosis of advanced disease and low tumor burden
might especially benefit from mitotane monotherapy, whereas patients with early
advanced disease and high tumor burden are probably better candidates for combined
therapy of mitotane and cytotoxic drugs.
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Dear Dr. Robertson,  
 
we are grateful for the constructive comments of the reviewers, which helped us to improve 
our manuscript significantly.  
Below you find our answers to the criticisms of the reviewers. We have addressed their 
queries in a step by step manner. All changes made in the manuscript are marked by the 
track function. 
We hope that, the revised version is now acceptable for publication in “The Journal of Clinical 
Endocrinology & Metabolism" 
 
Yours sincerely 
 
Martin Fassnacht 
 
 
 
Reviewers' Comments: 
Reviewer #1: The management of adrenocortical carcinoma (ACC) remains a major 
challenge and although mitotane has been used for many years, there are still a number of 
questions around its use and often the outcomes remain dismal. The only data we have to 
work from is, as noted by the authors, limited studies and/or retrospective studies. The 
present study involves a substantial number of patients from three centres in Germany; it is 
"a large clinical audit" or a "multicentre experience". The authors highlight one of the 
weaknesses, being the lack of either a control group or an appropriate comparator. There 
are, however, points of clinical relevance that would be of interest to those challenged by the 
management of these patients. The need for careful attention to serum mitotane levels is 
clearly reinforced by this study. Similarly, the lack of any meaningful efficacy in a very 
aggressive disease is also highlighted. One is certainly left with a clear impression that we 
still need improved therapeutics for this condition. That patients with a late recurrence do 
better on mitotane seems hardly surprising, by definition they are likely to be less aggressive 
tumours. I was not entirely clear why the authors seemed a little surprised by this?  
Response: We are grateful that the reviewer came to same key conclusions as we did 
and that he/she appreciated the value of our work. We agree with the reviewer that 
“surprise” is probably the wrong wording and we revised the corresponding parts of 
the article (line 232ff). What was indeed not clear to us in advance (and had never 
really been demonstrated) is the fact that mitotane seems to be more effective in less 
aggressive tumors.  
 
 
The other confounder in this type of study is that not only does it not have a control group, 
but the patients are subject to a range of selection biases, reflecting the Centre's and 
clinicians different approaches and to the selection of patients for treatment. 
Response: We fully agree with the reviewer and have emphasized this aspect even 
further (line 295ff).  
 
 
The paper would benefit from careful proofing, in some places the English is a little disjointed 
e.g. 
line 80 "Overall response rate is reported …… highly desirable" - needs to be rephrased. 
Line 93 "Treatment have not finally been clarified" - that sentence needs rephrasing. 
Point-by-Point Rebuttal
Line 215 "There are no doubts that these trials…." is a colloquial mistranslation. 
Line 216 ".. the patients of our sample are not ….." - rephrase. 
Line 255 "..immortal time bias" - I have no idea what this means.  
Response: We thank the reviewer for these helpful hints and corrected the English as 
mentioned above and supplemented an explanation of immortal time bias (264ff). 
 
 
Overall, the discussion is arguably too long and carries a little repetition. Given the limitations 
of this study and the relatively simple message that comes from it, it may be better 
substantially condensed perhaps even, if the Editors allow, with a merge of the Results and 
Discussion sections? 
Response: As suggested the Discussion has significantly shortened (old version 1565 
words vs. 1079 words in the new version), although we added several new arguments 
(as suggested by the reviewers). 
 
 
In conclusion, although there is a sense in which this is by its nature not formally scientifically 
rigorous, it does represent the reality of this condition and the information is of value and 
importance for training clinicians. 
Response: Again we would like to express our thanks to the reviewer for this 
supportive conclusion.  
 
 
 
Reviewer #2: In the manuscript by Megerle and colleagues, a retrospective study was 
conducted on mitotane efficacy for the treatment of advanced adrenocortical carcinomas. As 
mentioned by the authors, this is the largest study gathering clinical data from 1997 to 2016. 
Due to this long interval (19 years), several issues must be addressed. 
- The year 2005 appears to be a boundary in the lysodren dose that the patients received 
and the way mitotane concentration is determined. Is the starting dose before and after 2005 
has any influence on the objective response rate claimed by the authors?  
Response: We agree with the reviewer that the long study period and modifications in 
mitotane monitoring are relevant issues. However, only 19 patients have been treated 
before 2005 with quite similar outcome. In this subgroup objective responses were 
found in 31.6%, stable disease in 5.2%, and progressive disease in 63.2% of patients, 
whereas after 2005 (n=108) the rate of objective responses was 18.5%; of stable 
disease 28.7%, and of progressive disease 65%. Due to the small sample size before 
2005, we suggest not to add these results to the paper. Nevertheless, we mention now 
the number of patients before 2015 (line 136) and discuss the issue with the long 
study period and difference in mitotane management over time as limitation in the 
Discussion (line 309ff).  
 
 
Moreover is there any potential impact on the mitotane concentration determined by different 
laboratories?  Is there possibility that the measurement might be variable and should be 
taken into account? 
Response: We are sorry, but the fact that only 19 patients were treated before 2015 
and that 3 different labs had performed the analysis prevented a meaningful analysis. 
However, at the time we switched to the Lysosafe service we performed in several 
patients a cross-validation and did not find relevant differences.  
  
How does the mitotane dose used at initiation influence the time interval to reach plasma 
significance? 
Response: The reviewer is certainly right that the initial dosage should have some 
impact on the time interval to reach the target plasma level. Unfortunately, in this 
retrospective analysis it was not possible to have the exact daily dose of all patients 
throughout the treatment period. However, in 2012 we published a prospective study 
on exactly this topic (Kerkhofs et al. JCEM 2012). In this study with 40 patients we 
have seen some trend to a shorter median time to reach a plasma mitotane level of 14 
mg/l in the group with the higher starting dose, but this was not statistically significant 
(46 days (range 18-81 days) vs. 55 days (range 46-74 days); p= 0.29). Furthermore, in 
our current analysis and the multicenter study from 2012 there was a high inter-
individual variability. We comment on this aspect now in the Discussion (line 268ff). 
 
 
In the subgroup of cortisol-secreting tumors, Cushing's syndrome does cause significant 
morbidity and mortality due to edema, infections, and metabolic derangements. Mitotane 
should improve hormone overproduction, but if not, had those patients been treated for 
hypercortisolism? 
Response: We agree with the reviewer that Cushing’s syndrome can significantly 
influence morbidity and mortality. However, in this retrospective analysis we were not 
able to retrieve exact data on Cushing-related morbidity (this is often even difficult in 
prospective studies). Regarding mortality, we performed two analyses: one defined 
cortisol-producing ACC by biochemical evidence and here are the results given in 
Table 2 (lower panel): There was only a small trend for an increased mortality (HR for 
death for the not cortisol-producing tumors 0.94 (95% CI 0.56-1.57)). Following the 
comment of the reviewer, we now performed an additional analysis, in which we 
compared only patients with overt Cushing’s syndrome with all other patients. 
However, again we did not found a significant difference (HR 0.95 (95% CI 0.62 – 1.57). 
Of note, only 34 patients had an overt Cushing’s syndrome, and only 5 of them were 
treated with metyrapone or ketoconazole, respectively. This important aspect is now 
discussed (line 283ff). 
 
 
Line 199: "Index" should be changed for "index". 
Line 238: the colon should be changed for a full stop. 
Line 293: the sentence should be changed because it is confusing. The Ki67 index is not an 
easy marker to measure in patients with ACC. 
Response: We thank the reviewer for these helpful hints, which we corrected as 
suggested in the 3 comments above.  
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Abstract 45 
 46 
Context 47 
While mitotane is the only approved drug for the treatment of adrenocortical carcinoma (ACC), data on 48 
monotherapy in advanced disease is still scarce.  49 
Objective 50 
To assess the efficacy of mitotane in advanced ACC in a contemporary setting and to identify predictive factors  51 
Design/Setting 52 
Multicenter cohort study of three German referral centers 53 
Patients 54 
127 patients with advanced ACC treated with mitotane monotherapy 55 
Outcome measures 56 
RECIST evaluation. Progression-free and overall survival (PFS, OS) by Kaplan-Meier method. Predictive factors 57 
by Cox-regression. 58 
Results 59 
Twenty-six patients (20.5%) experienced objective response including three with complete remission. Overall, 60 
median PFS was 4.1 months (range 1.0-73) and median OS 18.5 months (range 1.3–220). Multivariate analysis 61 
indicated two main predictive factors: low tumor burden (<10 tumoral lesions): hazard ratio (HR) for progression of 62 
0.51(p=0.002) and for death of 0.59(p=0.017), and initiation of mitotane at delayed advanced recurrence: HR 63 
0.35(p<0.001) and 0.34(p<0.001), respectively. Accordingly, 67% of patients with low tumor burden and mitotane 64 
initiation ≥360 days after primary diagnosis experienced a clinical benefit (stable disease >180 days). Patients 65 
who achieved mitotane levels >14 mg/l had significantly better OS (HR 0.42; p=0.003). 66 
Conclusions 67 
With 20.5% the objective response rate was slightly lower than previously reported. However, more than 20% of 68 
patients experienced a long-term disease control >1 year. In general, patients with late diagnosis of advanced 69 
disease and low tumor burden might especially benefit from mitotane monotherapy, whereas patients with early 70 
advanced disease and high tumor burden are probably better candidates for combined therapy of mitotane and 71 
cytotoxic drugs.  72 
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1. Introduction 73 
Adrenocortical carcinoma (ACC) is a rare and aggressive disease with dismal prognosis and limited therapeutic 74 
options in advanced tumor stages [(1, 2]). Mitotane is the only drug approved for treatment of ACC and has been 75 
in clinical use both in an adjuvant and palliative setting for many years [(3-5]). However, data on the benefit of 76 
mitotane treatment are limited. 77 
Although the approval of mitotane in most countries is restricted to ACC not amenable to complete resection, data 78 
on mitotane monotherapy in advanced ACC are scarce [(2]). In fact, only 11 series with >10 patients have 79 
reported a total number of 395 patients treated with mitotane monotherapy in advanced disease. InOf these 80 
studies (3 prospective [(6-8]), 8 retrospective [(3, 9-15])) the largest series of patients enrolledincluded just 67 81 
patient in a singlean retrospective evaluation was 67. Overall response rate is reported only at about 25% clearly 82 
indicating that%. Therefore, factors of response prediction would be highly desirablehelp clinicians to choose the 83 
right treatment for each individual patient. Furthermore, the relevance of these studies for contemporary medicine 84 
is likely to be limited since most of the studies had been performed in or even before the 1990’s. Accordingly, in 85 
the majority of studies tumor response assessment was very heterogeneous and criteria are mostly not 86 
comparable with RECIST criteria, which are now standard of care and major outcomeendpoint in oncology 87 
studies.cancer trials. Of note, according to the labeling of mitotane in several countries (e.g. Europe Union) the 88 
effects of mitotane in non-functioning tumors has not been established. However, data supporting or disproving 89 
this statement are actually completely lacking. While the interest in mitotane as a sole first-line therapy in 90 
advanced ACC has increased recently, the lack of convincing data on monotherapy has unsettled clinicians. One 91 
reason for this "revival" of mitotane monotherapy comes indirectly from the FIRM-ACT trial. The results of this first 92 
randomized trial in ACC suggested that the most effective therapy, the combination of etoposide, doxorubicin, 93 
cisplatin, and mitotane, is as effective as second-line therapy as it is as first-line therapy [(16]). Therefore, it seems 94 
to be justified to test other drugs (e.g. mitotane) first without risking the lives of the patients.  95 
TheDespite efforts from several groups, the mechanisms of action of mitotane treatment have not finally been 96 
clarified despite efforts from several groups. Although we had recently demonstrated that mitotane induces 97 
endoplasmatic reticulum stress specifically in adrenocortical carcinoma cell lines and identified inhibition of sterol 98 
O-acyltransferase 1 (SOAT1) as a key molecular event [(17]), other mechanisms are likely to be relevant and may 99 
overlap when considering the high mitotane concentrations required for efficacy. In addition, pharmacokinetic 100 
properties including basic aspects such as intestinal resorption and metabolic transformation have only been 101 
partially elucidated.  102 
Several small studies suggested the importance of drug monitoring in the management of patients with mitotane. 103 
First, in 1984 van Slooten and colleagues had measured mitotane blood levels in 34 patients and found a relation 104 
to the response rate [(14]). This concept was then confirmed in a larger retrospective series (n=58) [(11]) and a 105 
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small prospective study (n=13) [(8]). Since that time most authors recommend aiming at plasma mitotane levels 106 
between 14 and 20 mg/l to improve response rate and to limit toxicity [(1, 2]).  107 
In the current large cohort study we analyze 127 patients with advanced ACC treated at three German centers 108 
with the aim to provide efficacy data on mitotane monotherapy based on contemporary imaging methods and to 109 
identify for the first time predictive factors for treatment response to mitotane.  110 
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2. Subjects and Methods 111 
A. Study population 112 
Patients and clinical and histological parameters (sex, age at diagnosis, tumor size, evidence of hormone excess, 113 
and tumor stage according to the European Network for the Study of Adrenal Tumors (ENSAT) classification 114 
[(18]), date of documented unresectability, Weiss score, Ki67 index, presence, site, size and number of tumor 115 
lesions, mitotane plasma concentration, and follow-up information) were retrieved from the German ACC Registry 116 
and the ENSAT Registry (www.ensat.org/registry). Both registries have been approved by the ethics committee of 117 
the University of Würzburg (approval number 86/03 and 88/11). The study is part of the German Adrenocortical 118 
Carcinoma Study group (ClinicalTrials.gov Identifier: NCT00453674). Written informed consent was obtained from 119 
all patients. Patients from three German centers (Würzburg, Berlin, Munich) were included who fulfilled the 120 
following eligibility criteria: age ≥18 years, histologically confirmed ACC, advanced (i.e. not completely resectable) 121 
disease at initial diagnosis or during the course of the disease; mitotane monotherapy for at least 30 days, cross 122 
sectional imaging (abdominal and thoracic CT, MRI or FDG-PET/CT) before start of mitotane therapy (≤30 days) 123 
and regularly during mitotane treatment (at least every 4 months in the first year; median 93 days). To ensure use 124 
of contemporary imaging methods and sufficient follow-up, inclusion was restricted to patients with a start of 125 
mitotane treatment between 01. Jan 1997 and 31. Dec 2016. Exclusion criteria were: incomplete information on 126 
primary diagnosis and/or follow-up, concomitant therapies such as radiotherapy or cytotoxic chemotherapy, and 127 
previous therapy with mitotane.  128 
B. Mitotane dosage and drug monitoring 129 
Mitotane was given as tablets (Lysodren®, Bristol Myers Squibb, Princeton, U.S.A. before 2004, then HRA 130 
Pharma, Paris, France). Before 2005, the drug was administered at doses usually not exceeding 3.5 g per day 131 
[(19]). After 2005, in most cases a high-dose starting schedule introduced by Baudin and colleagues [(20, 21]) was 132 
employed with a median maximal dosage of 7.5 g mitotane per day. Starting from 2005 mitotane plasma levels 133 
were measured centrally using the Lysosafe ® service (www.lysosafe.com). Before this service was available 134 
mitotane was analyzed in three different German laboratories that offered blood concentration assessment of 135 
mitotane. However, only 19 of our 127 patients did start mitotane before 2005.  136 
C. Response assessment 137 
Treatment response was recorded according to routine radiologic assessment and qualified as complete 138 
response, partial response, progressive disease, and stable disease in analogy to the Response Evaluation 139 
Criteria In Solid Tumors Version 1.1 (RECIST 1.1, [(22])). In uncertain cases (n=12), RECIST 1.1 was applied by 140 
reviewing all images by a blinded radiologist (W.S.).  141 
 142 
Field Code Changed
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 143 
D. Statistical analysis 144 
Progression-free survival (PFS) was defined as the interval between start of mitotane therapy and first 145 
documentation of progressive disease during follow-up or censored at last follow-up. Overall survival (OS) was 146 
calculated as the time between start of mitotane therapy and death, with censoring at last follow-up otherwise. 147 
PFS and OS were evaluated by the Kaplan-Meier method. We defined meaningful clinical benefit as disease 148 
control of more than 180 days, because in a recent placebo-controlled trial none of the patients without active 149 
treatment experienced disease stabilization for more than 150 days (23). The following potential prognostic and 150 
predictive factors were defined prior to the analysis: age (dichotomized at the median), sex, endocrine activity, 151 
Ki67 index of the primary tumor, tumor burden, pattern of affected organs at start of mitotane therapy, peak 152 
mitotane blood concentration during monotherapy or within the first 3 months of treatment, and timing of the 153 
mitotane initiation. In this context patients were classified according to the question whether mitotane treatment 154 
was initiated for advanced disease at time of initial diagnosis or at recurrence at a certain time during follow-up. In 155 
the latter case (treatment for recurrent advanced disease) we differentiated patients according the time between 156 
primary diagnosis and start of mitotane (< 360 days, 360-999 days, or ≥ 1000 days). All factors were investigated 157 
by univariate analysis using Cox regression. In case of p-value of below 0.1 in univariate analysis multivariate 158 
analyses were performed. Tumor burden was assessed in the multivariate analysis only as the sum of tumoral 159 
lesions. Association between variables and PFS/OS was expressed as hazard ratio (HR) and 95% confidence 160 
interval (CI). Statistical significance was set at p<0.05. For calculation of possible differences in response rate 161 
dependent on mitotane blood level “Fisher Exact Test” was used. Results are presented as median and range if 162 
not stated otherwise. For statistical calculation SPSS 24.0 (IBM Corp., Armonk, NY) was used.   163 
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3. Results 164 
At time of analysis (March 2017) 127 patients (female:male 77:50) were included. 49 patients (38.6%) suffered 165 
from advanced ACC at initial diagnosis and did start mitotane therapy within 3 weeks after establishment of the 166 
diagnosis. 78 patients (61.4%) started mitotane after experiencing recurrence with unresectable disease during 167 
follow-up. Median age was 58.6 years with a range of 19.8 to 85.8 years. Other baseline characteristics are given 168 
in Table 1.  169 
A. Best objective response, progression-free and overall survival 170 
Best response was complete response in three patients (2.4 %), partial response in 23 (18.1 %) and stable 171 
disease (SD) in 32 patients (25.2 %). Of the patients with SD, disease was controlled in 23 of them for at least 180 172 
days. 69 patients (54.3 %) had progressive disease at the time of first tumor evaluation. PFS was 4.1 months 173 
(range 1 – 73 months) and OS was 18.5 months (1.3 – 220 months) after initiation of mitotane (Figure 1). Overall, 174 
50 patients (40.9%) experienced clinical benefit (disease control > 180 days), including 28 (22.0%) with a long-175 
term benefit of more than 12 months.  176 
B. Predictive factors of progression-free and overall survival 177 
To identify possible predictive factors univariate and multivariate analyses (adjusted by age, sex, tumor burden, 178 
timing of mitotane initiation) were performed. Results are given in Table 2 and Figure 2. In short, univariate 179 
analyses showed better prognosis regarding PFS and OS for patients with Ki67 index <10%, mitotane initiation at 180 
delayed advanced recurrence (≥360d after initial diagnosis) and low tumor burden represented by <10 tumoral 181 
lesions. Multivariate analyses only indicated a better outcome for low tumor burden (PFS: HR 0.51, p=0.002, CI 182 
0.33-0.79; OS: HR 0.59, p=0.0017, CI 0.39-0.91) and timing of mitotane initiation at delayed advanced recurrence 183 
(HR for PFS: 0.35, p<0.001, CI 0.23-0.55 and HR for OS: 0.34, p<0.001, CI 0.22-0.52). For detailed analysis 184 
including subgroups see Table 2.  185 
C. Influence of mitotane drug levels on efficacy 186 
Patients who reached mitotane blood levels ≥14 mg/l had both superior PFS and OS as compared to patients in 187 
whom this blood concentration was not achieved (Table 3). Given that the association with response might be 188 
confounded by the long time interval required to reach a significant plasma concentration, we performed a 189 
subgroup analysis in which only mitotane levels in the first 3 months were considered. Here, the effect was 190 
statistically not significant. Remarkably, the 15 patients, who reached a level >20 mg/l within these first 3 months 191 
had a median PFS of 277 days (Table 3). Objective response rate in patients with mitotane level ≥14 mg/l was 192 
also significantly higher compared to <14 mg/l (31.9% vs. 11.1%; p=0.041). However, there were two patients with 193 
partial and one patient with complete response, whose peak level never was above 13 mg/l, including one patient 194 
with partial response and a maximum documented level below 10 mg/l.  195 
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D. Response rate in different subgroups 196 
In a next step we checked response rates to mitotane monotherapy in subgroups defined by potential predictive 197 
factors suggested by the present study or previous studies (9, 24-26). We found objective response rates (PR, 198 
CR) were highest (30%) in patients with both low tumor burden and mitotane initiation at delayed advanced 199 
recurrence (≥ 360 days after initial diagnosis) (Table 4). In contrast no objective response was seen in patients 200 
with both high tumor burden and mitotane initiation at initial diagnosis or early recurrence (< 360 days after 201 
primary diagnosis). Furthermore, in this subgroup only 6.3% experienced a clinical benefit (> 180 days), whereas 202 
such a benefit was present in more than 67% of patients in the complementary group (Table 4). Additionally, in 203 
54% patients with low Ki67 Indexindex (≤ 10 %) long-term disease control was achieved in comparison to only 24 204 
% with Ki67 > 20%.  205 
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4. Discussion 206 
Although mitotane is the only approved drug for the treatment of ACC patients, reliable data on mitotane 207 
monotherapy are surprisingly scarce. Here, we present the by far largest study analyzing the effects of mitotane 208 
monotherapy in 127 patients with advanced disease. We demonstrate that mitotane leads to an objective 209 
response rate of 21% (including 3 patients with complete response). Furthermore, additional 25 % of patients 210 
experienced stable disease translating to a median progression-free survival of 4.1 months and overall survival of 211 
18.5 months.  212 
In addition to providing contemporary efficacy data on mitotane, a further purpose of this study was to investigate 213 
potential prognostic and predictive factors in patients at mitotane therapy. In fact, we were able to identify a 214 
subgroup of patients (e.g. with late diagnosis of non-resectable disease and low tumor burden) that might benefit 215 
especially from mitotane monotherapy. Probably even more important from a clinical perspective, we did not 216 
observe any objective response and almost no clinical benefit in the group of patients who had advanced ACC 217 
within 12 months of the primary diagnosis and more than 10 tumoral lesions. Thus, in this subgroup additional 218 
therapeutic measures (e.g. cytotoxic chemotherapy with EDP [16]) seem to be justified or even necessary.  219 
Although a median progression-free survival of four months is not impressive, it compares favorably to other drugs 220 
investigated in ACC (23, 27-30) ((for review see [(2])). However, there are no doubts thatwithout a doubt these 221 
trials are not readily comparable (e.g. for different imaging intervals). Furthermore, the patients of our sample are 222 
not necessarily representative for a cohort of advanced ACC, because patients that were judged as harboring 223 
aggressive tumors might have been selected for the immediate start of adjunctive cytotoxic chemotherapy. 224 
Moreover, this study lacks an untreated comparator group, which renders demonstration of a direct causal 225 
relationship between treatment and disease stabilization impossible. However Nevertheless, this study clearly 226 
shows that mitotane is capable to induce objective response in a relevant percentage of patients and can control 227 
advanced disease at least in a subgroup for a long time. 228 
Despite the limitations of several earlier studies on mitotane monotherapy in the literature, the objective response 229 
rate in our study of 21% is surprisingly close to those from previously reported results [3,6-14], which had a mean 230 
response rate of 27% [2].  231 
One of the more surprising resultsA key result of our study is the observation that patients that started mitotane 232 
after late recurrence did much better than those patients who had advanced disease at the time of the initial 233 
diagnosis. An important and known aspect to consider might beis that patients with late recurrence have a 234 
generally better prognosis, because these tumors are usually less aggressive (31). However, this does notdoesn't 235 
necessarily explain the higher objective response rate in this cohort (Table 4). High tumor burden, described by 236 
maximal tumor diameter and/or number of tumoral lesions or organs, is associated with poor prognosis in 237 
literature (2, 32). Here, we could confirm that tumor load is an important prognostic factor. There is a significant 238 
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better PFS and OS in multivariate analysis in patients with advanced ACC and low tumor burden treated with 239 
mitotane. Of note, our data seems to suggest that low tumor burden is also a predictive factor for response to 240 
mitotane treatment, as 71% of patients with less than 10 tumoral lesions experienced disease control for more 241 
than 6 months, whereas this was the case in only 18% of patients with higher tumor load. 242 
Regarding Ki67 index, there was a slightly earlier progression in patients with Ki67 of ≥ 20 % in comparison to 243 
patients with Ki67 index ≤10 % in the primary tumor. However, this trend disappeared in multivariate analysis. 244 
Furthermore, patientsPatients with Ki67 index ≤10 % had a better overall survival than patients with Ki67 index ≥ 245 
20 %: With this endpoint, the effect was only visible as trend after multivariate analysis (HR 0.52; p=0.08).%. 246 
These results are in line with previous studies [24] that described Ki67 as an important prognostic marker in ACC, 247 
which however appears to have less discriminative value in advanced disease (33). Again, tumors with low Ki67 248 
seem to respond slightly better than tumors with high proliferative activity. However, one has to acknowledge that 249 
Ki67 staining of the primary tumor is most likely not the ideal parameter to judge the clinical behavior of a tumor 250 
that recurred in almost half of the patients more than 1 year after the initial surgery.  251 
Due to the fact that the disease can be controlled for more than 6 months in only 40% of patients, additional 252 
markers that could predict response to mitotane would be highly desirable. Expression of SOAT1 has been 253 
suggested as such a marker in a small cohort of patients [17].  254 
Taking these key findings together, our hypothesis is that less aggressive tumors might respond better to 255 
mitotane. Therefore, it could be reasonable to offer patients with late recurrence, low grade tumor and limited 256 
tumor burden mitotane monotherapy. In contrast, patients with aggressive disease probably benefit more from 257 
early administration of cytotoxic drugs. 258 
 259 
Mitotane therapy and mitotane blood levels have shown to be correlated with objective response rate and also 260 
PFSprogression-free and/or OSoverall survival in patients with advanced or recurrent ACC (8, 9, 11, 34). In our 261 
study a trend towards better PFSprogression-free survival with higher peak mitotane blood levels during therapy 262 
could be seen in multivariate analysis. Regarding OSoverall survival, results show a significant correlation 263 
between higher mitotane levels and longer OSsurvival. However, the so called immortal time bias may partially 264 
explain this finding, meaning that higher mitotane levels correlate with treatment duration and this certainly comes 265 
with longer survival. If we used only the mitotane measurements in the first three months of therapy, there was no 266 
significant correlation with progression-free or overall survival. However, the number of patients in this sub-267 
analysis might have been too small to draw strong conclusions. Furthermore initial dosage of mitotane might 268 
influence the time interval to reach relevant plasma levels, although an earlier analysis suggested no significant 269 
difference between two starting regimens in the first 12 weeks (21). Therefore, further studies on mitotane blood 270 
levels in the first weeks after initiation are warranted to investigate its value as predictive marker for outcome. Of 271 
noteInterestingly, we have seen objective response in three patients, who never reached the "therapeutic 272 
11 
 
concentration" of 14mg/l. Thus, a level ≥ 14mg/l seems to us still desirable, but lower levels do not preclude 273 
clinical benefit. 274 
Female to male ratio in our cohort matched previous reports, but median age was higher than shown in earlier 275 
reports [2,33]. This might be due to the fact that in the enrolled cohort there was a notable amount of patients with 276 
recurrence, which occurred partially years after first diagnosis. Another and more important reason is that young 277 
patients with advanced ACC might be often treated more aggressively with mitotane plus cytotoxic chemotherapy, 278 
which excluded them from this study.  279 
Regarding secretory status of ACC, severalSeveral studies have shown worse prognosis for cortisol-producing 280 
tumors (26, 35, 36). In our cohort we could not show any difference in progression-free and overall survival 281 
between patients with and without cortisol-producing ACC. This might be due to the small number of patients (n = 282 
80) of which we had sufficient information about the endocrine function of their ACC. Furthermore, only 34 283 
patients had overt Cushing's syndrome, but only 5 had to be treated with inhibitors of steroidogenesis suggesting 284 
that only a minority of the cohort had severe hypercortisolism not controlled by mitotane. However, our study 285 
provides important additional information for the official labeling of mitotane in several countries (e.g. in the 286 
European Union), where it is mentioned that the effects of mitotane in non-functioning tumors is not established. 287 
Our study clearly suggests that mitotane is effective independently of endocrine activity of the tumor. Therefore, 288 
we recommend - as it is already clinical practice in most expert centers - to administer mitotane in both, 289 
functioning and non-functioning tumors.  290 
Our study has obvious limitations: (i) Its retrospective design and the lack of a control group hinders a proper 291 
separation of the effect of mitotane from other known and unknown prognostic factors in ACC. However, a 292 
placebo-controlled trial might be even unethical, because it is well known that almost all ACC progress rapidly, if 293 
they are left untreated, as just recently prospectively demonstrated in the GALACCTIC trial (23). We also think 294 
that despite (ii) Furthermore, patients in our cohort are probably not representative for the lack of a formal 295 
controlentire group, we can draw relevant conclusions regarding the effectiveness of mitotane. The reason is that 296 
complete or partial response will not occur in ACC in the absence of treatment. This means that the numbers on 297 
response, whether partial or complete, provide valuable estimates of mitotane effect. Of course this does not 298 
beyond doubt answer the question what the optimal treatment regimen in  of advanced ACC is. (ii, because 299 
patients with aggressive tumors might have been selected for the immediate start of adjunctive cytotoxic 300 
chemotherapy. (iii) Another weakness is of course the relative small number of cases presented here that might 301 
havehas prevented statistically significant results in some interestingdetailed subgroup analyses. On the other 302 
hand, 127 patients can be considered a very large number in comparison to earlier reports. Most likely a cohort of 303 
more than 500 would be required to allow for a better statistical power and such a cohort size is currently unlikely 304 
to be achievable even in a worldwide effort. Furthermore, it seems to be unrealistic to gather funding for a large 305 
prospective observational trial for a drug that is already approved for many years.. Thus, it is likely that these 306 
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results are the most reliable results for the time being. (iii) Moreover, a complete endocrine workup was lacking in 307 
several of our patients, thereby hampering an in-depth analysis on the impact of hormonal hypersecretion in this 308 
situation. (iiiiiv) The same is true for certain other factors (like Ki67)long study period and the modification of the 309 
mitotane blood level in the first three monthsmanagement in 2005 might have influenced the results. However, the 310 
fact that only 19 patients were recruited before 2005 suggests that were just not available for all patients. (iiiiithe 311 
overall influence is limited. (v) Finally, we did not report adverse effects. However, it is well established that 312 
reliable data on adverse events require prospective data collection and to avoid underreporting we preferred not 313 
to elaborate on this issue.  314 
 315 
5. Conclusions 316 
This largest study on mitotane monotherapy demonstrated that this drug is able to achieve relevant clinical benefit 317 
for patients with advanced ACC. Although the objective response rate was slightly lower than reported previously, 318 
the fact that a fifth of the cohort had clear tumor shrinkage proves efficacy of the drug. This is further substantiated 319 
by the 20% of patients, who experienced a long-term disease control >1 year. Our study suggests that patients 320 
with less aggressive tumors (e.g. low grade tumors with low tumor burden and a long interval between initial 321 
diagnosis and necessity to start systemic therapy) might be especially good candidates for mitotane monotherapy. 322 
In contrast, patients with advanced disease at primary diagnosis and high tumor load probably benefit more from 323 
early administration of cytotoxic drugs. 324 
 325 
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Table 1. Clinical characteristics of the study cohort  
Parameter/Subgroup  
Entire cohort 127 
Age at start mitotane (yr) 
  Median 
  Range 
  ≤ 58 yrs 
 >58 yrs 
 
58.6 
19.8 – 85.8 
63 (49.6 %) 
64 (50.4 %) 
Sex 
  Female 
  Male  
 
77 (60.6 %) 
50 (39.4 %) 
BMI (kg/m2) (n=99) 
  Median 
  Range 
 
25.1 
17.2 – 42.9 
Endocrine activity of the primary tumor 
  Cortisol (+/- others) 
  Pure sex-hormones and precursors 
  Pure Aldosterone 
  No hypersecretion 
  Not determined 
 
49 (38.6 %) 
9 (7.1 %) 
2 (1.6 %) 
20 (15.7 %) 
47 (37 %) 
Predefined subgroup: endocrine activity (n=80) 
  Hypersecretion of cortisol 
  No hypersecretion of cortisol 
 
49 (61.2 %) 
31 (38.8 %) 
Ki67 index (%) (n=90) 
  Median 
  Range 
 
10 
1 – 70 
Ki67 index subgroups (n=90) 
  ≤ 10 % 
  10.1 – 20 % 
  > 20 % 
 
46 (51.1 %) 
22 (24.4 %) 
22 (24.4 %) 
Number of tumoral lesions at mitotane initiation 
  ≤ 2 lesions 
  3-4 lesions 
  5-9 lesions 
  ≥ 10 lesions 
 
28 (22.0 %) 
23 (18.1 %) 
21 (16.5 %) 
55 (43.3 %) 
Sum of diameter of all tumoral lesions at start mitotane (n=124) 
  ≤ 3 cm  
  3.1 - <10 cm 
  ≥ 10 cm 
 
19 (15.3 %) 
46 (37.1 %) 
59 (47.6 %) 
Affected organs 
  Lung only 
  Liver only 
  Local recurrence only  
  Others 
  Tumoral lesions at multiple localizations 
 
30 
10 
8 
14 
65 
Timing of mitotane initiation 
  at initial diagnosis (with advanced disease) 
  at early advanced recurrence (< 360 days since initial diagnosis) 
  at delayed advanced recurrence (360-999 days since initial diagnosis) 
  at delayed advanced recurrence (≥ 1000 days since initial diagnosis) 
 
49 (38.6%) 
22 (17.3%) 
33 (26%) 
23 (18.1%) 
Peak mitotane blood level during mitotane monotherapy (mg/l) (n=96) 
  Median 
  Range 
 
19.6 
2.5 – 66.4 
Peak mitotane blood level (n=96) 
 < 10 mg/l 
 10-13.9 mg/l 
 14-20 mg/l 
 > 20 mg/l 
 
13 (13.5 %) 
14 (14.6 %) 
33 (34.3 %) 
36 (37.5 %) 
Peak mitotane blood level after 3 months of therapy (mg/l) (n=74) 
  Median 
  Range 
 
13.05 
2.46 – 66.40 
Peak mitotane blood level after 3 months of therapy (n=74) 
 < 10 mg/l 
 10-13.9 mgl/l 
 14-20 mg/l 
 > 20 mg/l 
 
24 (32.4 %) 
13 (17.6%) 
22 (29.7 %) 
15 (20.2 %) 
 6 
All subgroups with less than 127 patients have been marked. Otherwise the complete cohort is included. Mitotane 7 
blood level was measured in total with 489 blood samples (Median 4 blood samples per patient, range 1-12)  8 
Tables Click here to download Table Megerle-Mitotane in advanced ACC -
tables.docx
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Table 2. Prognostic factors on progression-free and overall survival  
 
Prognostic factors on progression-free survival 
  
 
n 
Median 
PFS in 
days 
 
 
range 
 
Univariate analysis 
    HR         95% CI                P 
 
Multivariate analysis* 
    HR         95% CI            P 
Sex 127         
  Female 77 109 28-1518 1   1   
  Male 50 181 34-2196 0.69 0.46-1.03 0.07 0.85 0.56-1.29 0.45 
Age at start mitotane 127         
  ≤ 58 yr 63 117 28-1518 1.09 0.74-1.61 0.65    
  >58 yr 64 165 32-2196 1      
Endocrine activity 80         
  Cortisol-producing 49 102 28-1518 1      
  Not cortisol-producing 31 122 33-964 1.07 0.66-1.72 0.79    
Ki67 index 90         
  ≤ 10 % 46 197 46-948 0.63 0.36-1.1 0.10 0.80 0.43-1.5 0.50 
  10.1 % - 20 % 22 90 28-2196 1.06 0.54-2.06 0.86 1.07 0.52-2.2 0.85 
  > 20 % 22 92 33-644 1   1   
Number of tumoral lesions 127         
  ≤ 2 28 171 35-1079 0.57 0.35-0.94 0.027 0.53 0.31-0.92 0.023 
  3-4 23 139 35-746 0.52 0.29-0.92 0.026 0.48 0.26-0.91 0.025 
  5-9 21 185 52-2196 0.56 0.32-0.98 0.042 0.50 0.28-0.91 0.023 
  ≥ 10 55 83 28-1518 1   1   
Timing of mitotane initiation 127         
  at initial diagnosis 49 92 28-644 1   1   
  at early advanced recurrence  
    (< 360 days since initial 
    diagnosis) 
22 99 52-1079 0.56 0.32-0.98 0.041 0.65 0.35-1.2 0.17 
  at delayed advanced recurrence  
    (360-999 days since initial 
    diagnosis) 
33 232 32-1518 0.40 0.24-0.66 <0.001 0.33 0.19-0.56 <0.001 
  at delayed advanced recurrence  
    (≥ 1000 days since initial  
    diagnosis) 
23 269 49-2196 0.26 0.14-0.48 <0.001 0.27 0.14-0.50 <0.001 
 
Prognostic factors on overall survival 
  
 
n 
Median 
OS in 
days 
 
 
range 
 
Univariate analysis 
    HR         95% CI            P 
 
Multivariate analysis 
  HR            95% CI          P 
Sex 127         
  Female 77 553 39-6611 1      
  Male 50 556 70-3848 0.78 0.52-1.18 0.24    
Age at start mitotane 127         
  ≤58 yr 63 621 39-6611 0.88 0.60-1.31 0.55    
  >58 yr 64 511 40-4033 1      
Endocrine activity 80         
  Cortisol-producing 49 555 39-3603 1      
  Not cortisol-producing 31 531 40-6611 0.94 0.56-1.57 0.82    
Ki67 index 90         
  ≤10 % 46 754 72-4033 0.36 0.20-0.67 0.001 0.52 0.25-1.08 0.08 
  10.1 % - 20 % 22 512 70-2572 0.75 0.40-1.42 0.38 0.77 0.37-1.57 0.47 
  >20 % 22 374 39-2432 1   1   
Number of tumoral lesions 127         
  ≤ 2 28 790 81-4033 0.63 0.38-1.06 0.08 0.55 0.32-0.96 0.035 
  3-4 23 711 64-3820 0.65 0.38-1.13 0.13 0.55 0.31-0.99 0.047 
  5-9 21 553 251-2660 0.78 0.44-1.38 0.39 0.70 0.39-1.29 0.26 
  ≥10 55 433 39-6611 1   1   
Timing of mitotane initiation 127         
  at initial diagnosis 49 389 39-3848 1   1   
  at early advanced recurrence  
    (< 360 days since initial 
diagnosis) 
22 415 64-3820 0.69 0.40-1.2 0.18 0.78 0.44-1.38 0.39 
  at delayed advanced recurrence  
    (360-999 days since initial 
diagnosis) 
33 874 59-6611 0.38 0.23-0.63 <0.001 0.33 0.2-0.57 <0.001 
  at delayed advanced recurrence  
    (≥ 1000 days since initial 
diagnosis) 
23 863 72-4033 0.31 0.17-0.56 <0.001 0.27 0.14-0.51 <0.001 
 9 
Only possible prognostic factors that showed at least a trend (p ≤ 0.10) in univariate analysis were further 10 
investigated by multivariate analysis (adjusted by age, sex, tumor burden, timing of mitotane initiation). Subgroups 11 
with less than 127 patients in total were analyzed separately (adjusted by age, sex, tumor burden, timing of 12 
mitotane initiation)  13 
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Table 3. Influence of Mitotane blood level on progression-free and overall survival  
 
Influence of Mitotane blood level on progression-free survival 
  
 
n 
Median 
PFS in 
days 
 
 
range 
 
Univariate analysis 
    HR         95% CI                P 
 
Multivariate analysis* 
    HR             95% CI            P 
Peak mitotane blood level 96         
 <10 mg/l 13 77 34-667 1   1   
 10 – 13.9 mg/l 14 146 32-509 0.73 0.32-1.66 0.46 0.71 0.29-1.74 0.45 
 14 – 20 mg/l 33 208 39-2196 0.40 0.19-0.83 <0.05 0.55 0.24-1.27 0.16 
 >20 mg/l 36 181 28-1518 0.42 0.20-0.85 <0.05 0.49 0.22-1.2 0.09 
Peak mitotane blood level 
within 3 months 
74         
 <10 mg/l 24 125 32-1079 1      
 10 – 13.9 mg/l 13 179 38-644 0.82 0.37-1.81 0.62    
 14 – 20 mg/l 22 144 39-2196 0.85 0.45-1.64 0.64    
 >20 mg/l 15 277 52-1518 0.64 0.31-1.34 0.23    
 
Influence of Mitotane blood level on overall survival 
  
 
n 
Median 
OS in 
days 
 
 
range 
 
Univariate analysis 
    HR         95% CI               P 
 
Multivariate analysis* 
    HR             95% CI             P 
Peak mitotane blood level 96         
 <10 mg/l 13 262 70-1599 1   1   
 10 – 13.9 mg/l 14 502 46-2577 0.60 0.28-1.30 0.2 0.35 0.15-0.83 0.017 
 14 – 20 mg/l 33 814 106-3820 0.29 0.14-0.58 0.001 0.26 0.12-0.59 0.001 
 >20 mg/l 36 770 84-6611 0.25 0.12-0.51 <0.001 0.18 0.08-0.42 <0.001 
Peak mitotane blood level 
within 3 months 
74         
 <10 mg/l 24 685 70-2660 1      
 10 – 13.9 mg/l 13 535 46-1803 1.52 0.67-3.44 0.31    
 14 – 20 mg/l 22 857 90-2422 0.83 0.41-1.67 0.60    
 >20 mg/l 15 679 84-6611 0.62 0.28-1.38 0.24    
 14 
PFS: progression-free survival; OS: overall survival. Only possible prognostic factors that showed at least a trend 15 
(p ≤ 0.10) in univariate analysis were further investigated by multivariate analysis (adjusted by age, sex, tumor 16 
burden, timing of mitotane initiation)17 
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Table 4. Response to therapy in different subgroups 
 CR PR CR+PR SD Benefit>18
0d 
PD 
Timing of mitotane initiation 
  At initial diagnosis or at early recurrence (<  
  360 d since initial diagnosis) 
 
  At delayed advanced recurrence (≥ 360 d  
  since initial diagnosis) 
 
0 
 
 
3 (5.3 %) 
 
7 (9.9%) 
 
 
16 (28.6%) 
 
7 (9.9%) 
 
 
19 (33%) 
 
17 (24%) 
 
 
15 (26.7%) 
 
16 (22.5%) 
 
 
34 (60.7%) 
 
47 (66.2%) 
 
 
22 (39.3%) 
Number of tumoral lesions 
 <10 
 
 ≥10 
 
2 (2.7%) 
 
1 (1.8%) 
 
6 (8.3%) 
 
17 (30.9%) 
 
8 (15.7%) 
 
18 (23.7%) 
 
22 (30.5%) 
 
10 (18.1%) 
 
36 (70.6%) 
 
14 (18.4%) 
 
21 (41.2%) 
 
48 (63.2%) 
Ki67 (n=90) 
  ≤ 10 % 
 
  10.1 % - 20 % 
 
  > 20 % 
 
1 (2.2%) 
 
0 
 
0 
 
11 (23.9%) 
 
4 (18.1%) 
 
3 (13.6%) 
 
12 (26%) 
 
4 (18.1%) 
 
3 (13.6%) 
 
15 (32.6%) 
 
4 (18.1%) 
 
3 (13.6%) 
 
25 (54.3%) 
 
2 (8.7%) 
 
  5 (23.8%) 
 
19  (41.3 %) 
 
15  (65.2 %) 
 
15  (71.4 %) 
Endocrine activity (Cortisol, n=80) 
  Yes 
   
  No  
 
1 (2%) 
 
0 
 
8 (16.3%) 
 
10 (32.2%) 
 
9 (18.4%) 
 
10 (32.2%) 
 
6 (12.2%) 
 
10 (32.2%) 
 
16 (32.6%) 
 
13 (41.9%) 
 
16 (51.6%) 
 
29 (59.0%) 
Cohort who fulfilled the following criteria:  
  At initial diagnosis or at early recurrence  
  (<360 d since initial diagnosis) +  
  ≥10 tumoral lesions (n=32) 
 
  At delayed advanced recurrence (≥ 360 d  
  since initial diagnosis) +  
  <10 tumoral lesions (n=33) 
 
 
0 
 
 
2 (6%) 
 
 
0 
 
 
8 (24.2%) 
 
 
0  
 
 
10 (30.3%) 
 
 
3 (9.3%) 
 
 
11 (33.3%) 
 
 
2 (6.3%) 
 
 
22 (66.7%) 
 
 
29 (90.6%) 
 
 
12 (36.4%) 
 
CR=complete response, PR=partial response, SD=stable disease, PD=progressive disease, Benefit = SD, PR or 
CR for >180 days 
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